Patent ID: 11919890
Assignee: ELI LILLY AND COMPANY
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method, comprising contacting a receptor-interacting protein-1 (RIP1) kinase in a subject with a compound, a pharmaceutically acceptable salt thereof, or both the compound and the pharmaceutically acceptable salt thereof; or a pharmaceutical composition comprising the compound and/or the pharmaceutically acceptable salt thereof, and wherein the compound has a formula, or a pharmaceutically acceptable salt thereof, wherein:
ring B is 5-membered heteroaryl;
L is a C1-10aliphatic linker;
R1 is Ra or Rb wherein at least one R1 is Rb;
each of R2 and R3 independently are Ra;
each R4 and each R5 independently are Ra or Rb;
Ra is independently for each occurrence H, D, C1-10aliphatic, or C1-10cycloaliphatic;
Rb is independently for each occurrence halogen or —NRdRd wherein two Rd groups together with the nitrogen bound thereto provide a C3-10heterocyclic group optionally substituted with one or more Re or Rg;
Re is independently for each occurrence —ORa, —N(Ra)2, C1-6 alkyl, C1-6 haloalkyl, C1-6heteroalkyl, C3-6 cycloalkyl, or two Re groups join together to provide a C3-10heterocyclic group with the Rb group to which the two Re groups are bound;
Rg is independently for each occurrence halogen, C1-10aliphatic-C5-10aromatic, or ═O

m is 1 to 4;
n is 0, 1 or 2; and
p is 0, 1, 2, 3, 4, or 5,
wherein the subject has a disease involving a receptor-interacting protein-1 (RIP1) kinase, wherein the diseases involving a receptor-interacting protein-1 (RIP1) kinase is ankylosing spondylitis, rheumatoid arthritis, atopic dermatitis, psoriasis, or any combination thereof.